Page 15 - Zai Lab News Today

Argenx (NASDAQ:ARGX – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Volatility and Risk argenx has a beta of 0.79, […]

5G subscriptions will reach 550 million in Southeast Asia and Oceania by the end of 2029, according to the November edition of the Ericsson Mobility Report.

As generatlive AI platforms ingest greater oceans of data and get connected to more and more corporate databases, researchers are sounding an alarm: the tools are highly inaccurate and becoming more inscrutable.

Investment Analysts’ price target changes for Thursday, November 30th: Ameren (NYSE:AEE) had its price target cut by JPMorgan Chase & Co. from $90.00 to $89.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. AvalonBay Communities (NYSE:AVB) had its target price raised by Evercore ISI from $183.00 to $188.00. The firm currently […]

As generatlive AI platforms ingest greater oceans of data and get connected to more and more corporate databases, researchers are sounding an alarm: the tools are highly inaccurate and becoming more inscrutable.

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) and Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 86.9% of Intra-Cellular […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Analyst Ratings This is a summary of […]

Argenx (NASDAQ:ARGX – Get Free Report) and Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares argenx and Outlook […]

Rattled by Altman’s ouster after having invested an estimated $13 billion in OpenAI, Microsoft can now relax as the AI firm functions as before—under Altman, a new board and perhaps also under investor control for a change.